Literature DB >> 18049300

Practice parameter for the assessment and treatment of children and adolescents with depressive disorders.

Boris Birmaher, David Brent, William Bernet, Oscar Bukstein, Heather Walter, R Scott Benson, Allan Chrisman, Tiffany Farchione, Laurence Greenhill, John Hamilton, Helene Keable, Joan Kinlan, Ulrich Schoettle, Saundra Stock, Kristin Kroeger Ptakowski, Jennifer Medicus.   

Abstract

This practice parameter describes the epidemiology, clinical picture, differential diagnosis, course, risk factors, and pharmacological and psychotherapy treatments of children and adolescents with major depressive or dysthymic disorders. Side effects of the antidepressants, particularly the risk of suicidal ideation and behaviors are discussed. Recommendations regarding the assessment and the acute, continuation, and maintenance treatment of these disorders are based on the existent scientific evidence as well as the current clinical practice.

Entities:  

Mesh：

Year:  2007        PMID： 18049300     DOI： 10.1097/chi.0b013e318145ae1c

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN： 0890-8567            Impact factor:   8.829


  246 in total

1.  Social determinants of mental health treatment among Haitian, African American, and White youth in community health centers.

Authors:  Nicholas Carson; Ben Lê Cook; Margarita Alegria
Journal:  J Health Care Poor Underserved       Date:  2010-05

Review 2.  Computerised cognitive behavioural therapy for the prevention and treatment of depression and anxiety in children and adolescents: a systematic review.

Authors:  Thomas Richardson; Paul Stallard; Sophie Velleman
Journal:  Clin Child Fam Psychol Rev       Date:  2010-09

3.  Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.

Authors:  Hiwot Woldu; Giovanna Porta; Tina Goldstein; Dara Sakolsky; James Perel; Graham Emslie; Taryn Mayes; Greg Clarke; Neal D Ryan; Boris Birmaher; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Martin B Keller; David Brent
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-03-09       Impact factor: 8.829

4.  Survey of Minnesota parent attitudes regarding school-based depression and suicide screening and education.

Authors:  Claudia K Fox; Marla E Eisenberg; Barbara J McMorris; Sandra L Pettingell; Iris W Borowsky
Journal:  Matern Child Health J       Date:  2013-04

5.  Escitalopram in the treatment of major depressive disorder in adolescent patients. Profile report.

Authors:  Lily P H Yang; Lesley J Scott
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 6.  Screening for Depression in Pediatric Primary Care.

Authors:  Valerie L Forman-Hoffman; Meera Viswanathan
Journal:  Curr Psychiatry Rep       Date:  2018-07-23       Impact factor: 5.285

7.  A novel PDE9 inhibitor WYQ-C36D ameliorates corticosterone-induced neurotoxicity and depression-like behaviors by cGMP-CREB-related signaling.

Authors:  Xian-Feng Huang; Wen-Tao Jiang; Li Liu; Fang-Chen Song; Xia Zhu; Gui-Lan Shi; Shu-Ming Ding; Heng-Ming Ke; Wei Wang; James M O'Donnell; Han-Ting Zhang; Hai-Bin Luo; Yi-Qian Wan; Guo-Qiang Song; Ying Xu
Journal:  CNS Neurosci Ther       Date:  2018-05-02       Impact factor: 5.243

8.  Racial Disparity, Depression, and Birth Outcomes Among Pregnant Teens.

Authors:  Hala Abdelaal; Mohamed A Mohamed; Hany Aly
Journal:  Matern Child Health J       Date:  2018-10

Review 9.  Improving care for depression and suicide risk in adolescents: innovative strategies for bringing treatments to community settings.

Authors:  Joan Rosenbaum Asarnow; Jeanne Miranda
Journal:  Annu Rev Clin Psychol       Date:  2014-01-16       Impact factor: 18.561

10.  Fluoxetine exposure during adolescence alters responses to aversive stimuli in adulthood.

Authors:  Sergio D Iñiguez; Lyonna F Alcantara; Brandon L Warren; Lace M Riggs; Eric M Parise; Vincent Vialou; Katherine N Wright; Genesis Dayrit; Steven J Nieto; Matthew B Wilkinson; Mary K Lobo; Rachael L Neve; Eric J Nestler; Carlos A Bolaños-Guzmán
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.